Medical Center Saint Naum EOOD

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Depression9 trials
• Alzheimer disease3 trials
• Schizophrenia3 trials
• Bipolar disorder2 trials
• Lewy body dementia2 trials
• Insomnia1 trial
• Stroke1 trial

Phase

• Phase 314 trials
• Phase 24 trials
• Phase 2/32 trials

Status

• Completed9 trials
• Recruiting8 trials
• Suspended2 trials
• Active, not recruiting1 trial

Lead sponsor

• Karuna Therapeutics, Inc., a Bristol Myers Squibb company3 trials
• Neurocrine Biosciences3 trials
• ACADIA Pharmaceuticals Inc.2 trials
• Bristol-Myers Squibb2 trials
• Xenon Pharmaceuticals Inc.2 trials
• and 8 more

Running trials

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07095465· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06911112· Phase 3· Neurocrine Biosciences· Source

• Recruiting

  Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

  NCT06480383· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease3 recruiting
• Depression2 recruiting
• Lewy body dementia2 recruiting

Closed trials

• Completed

  A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

  2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source

• Completed

  A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine

  2023-507942-10-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

  2023-508163-74-00· Phase 3· Janssen Cilag International· Source

• Completed

  Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.

  2022-500538-27-00· Phase 2/3· Otsuka Pharmaceutical Development And Commercialization Inc.· Source

• Completed

  A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

  NCT05729373· Phase 2/3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05304767· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

  NCT05110157· Phase 3· Neurocrine Biosciences· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source